ALNYLAM PHARMACEUTICALS, INC. - Common Stock (ALNY)
CUSIP: 02043Q107
Q2 2018 13F Holders as of 30 Jun 2018
- Type / Class
- Equity / Common Stock
- Shares outstanding
- 131,516,365
- Total 13F shares
- 91,541,386
- Share change
- -140,951
- Total reported value
- $9,015,538,809
- Put/Call ratio
- 52%
- Price per share
- $98.49
- Number of holders
- 303
- Value change
- -$37,011,096
- Number of buys
- 174
- Number of sells
- 111
Quarterly Holders Quick Answers
What is CUSIP 02043Q107?
CUSIP 02043Q107 identifies ALNY - ALNYLAM PHARMACEUTICALS, INC. - Common Stock in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Related Filing Research
- Latest 13F filings for newly reported positions.
- Latest Schedule 13D/13G reports for ownership changes outside 13F cadence.
- Latest 10-Q/10-K reports for financial context tied to this issuer.
- Recent insider transactions for executive and insider activity.
- SEC investors directory and top value investors for manager drilldown.
- Back to full security ownership history.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 02043Q107:
Top shareholders of ALNY - ALNYLAM PHARMACEUTICALS, INC. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| FMR LLC |
13F
|
Company |
11%
|
15,025,708
|
$1,789,562,000 | — | 31 Mar 2018 | |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
|
Company |
9.6%
|
12,569,334
|
$1,497,008,000 | — | 31 Mar 2018 | |
| WELLINGTON MANAGEMENT GROUP LLP |
13F
|
Company |
7.3%
|
9,603,162
|
$1,143,737,000 | — | 31 Mar 2018 | |
| VANGUARD GROUP INC |
13F
|
Company |
5.7%
|
7,443,406
|
$886,511,000 | — | 31 Mar 2018 | |
| BlackRock Finance, Inc. |
13F
|
Company |
5.5%
|
7,178,062
|
$854,909,000 | — | 31 Mar 2018 | |
| DODGE & COX |
13F
|
Company |
3.6%
|
4,692,841
|
$558,917,000 | — | 31 Mar 2018 | |
| BAILLIE GIFFORD & CO |
13F
|
Company |
2.9%
|
3,834,213
|
$456,656,000 | — | 31 Mar 2018 | |
| STATE STREET CORP |
13F
|
Company |
1.6%
|
2,131,817
|
$253,903,000 | — | 31 Mar 2018 | |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC |
13F
|
Company |
1%
|
1,341,171
|
$159,733,467 | — | 31 Mar 2018 | |
| PERCEPTIVE ADVISORS LLC |
13F
|
Company |
0.97%
|
1,280,802
|
$152,543,000 | — | 31 Mar 2018 | |
| ORBIMED ADVISORS LLC |
13F
|
Company |
0.96%
|
1,265,966
|
$150,777,000 | — | 31 Mar 2018 | |
| MORGAN STANLEY |
13F
|
Company |
0.96%
|
1,260,422
|
$150,116,000 | — | 31 Mar 2018 | |
| GILDER GAGNON HOWE & CO LLC |
13F
|
Company |
0.92%
|
1,210,422
|
$144,161,000 | — | 31 Mar 2018 | |
| BB BIOTECH AG |
13F
|
Company |
0.77%
|
1,011,338
|
$120,450,000 | — | 31 Mar 2018 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.77%
|
1,010,738
|
$120,379,000 | — | 31 Mar 2018 | |
| Point72 Asset Management, L.P. |
13F
|
Company |
0.69%
|
908,046
|
$108,148,000 | — | 31 Mar 2018 | |
| NORGES BANK |
13F
|
Company |
0.61%
|
803,963
|
$95,751,000 | — | 31 Mar 2018 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.58%
|
765,344
|
$91,090,000 | — | 31 Mar 2018 | |
| 12 West Capital Management LP |
13F
|
Company |
0.53%
|
700,000
|
$83,370,000 | — | 31 Mar 2018 | |
| PICTET ASSET MANAGEMENT LTD |
13F
|
Company |
0.49%
|
646,038
|
$76,943,000 | — | 31 Mar 2018 | |
| Artal Group S.A. |
13F
|
Company |
0.46%
|
600,000
|
$71,460,000 | — | 31 Mar 2018 | |
| BRIDGER MANAGEMENT, LLC |
13F
|
Company |
0.42%
|
549,632
|
$65,461,000 | — | 31 Mar 2018 | |
| FIRST TRUST ADVISORS LP |
13F
|
Company |
0.41%
|
536,667
|
$63,917,000 | — | 31 Mar 2018 | |
| JANUS HENDERSON GROUP PLC |
13F
|
Company |
0.38%
|
504,311
|
$60,064,000 | — | 31 Mar 2018 | |
| Mitsubishi UFJ Trust & Banking Corp |
13F
|
Company |
0.37%
|
491,101
|
$58,490,000 | — | 31 Mar 2018 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.36%
|
471,776
|
$56,189,000 | — | 31 Mar 2018 | |
| DEUTSCHE BANK AG\ |
13F
|
Company |
0.34%
|
446,660
|
$53,193,000 | — | 31 Mar 2018 | |
| Polar Capital LLP |
13F
|
Company |
0.34%
|
441,232
|
$52,551,000 | — | 31 Mar 2018 | |
| FEDERATED HERMES, INC. |
13F
|
Company |
0.3%
|
401,043
|
$47,764,000 | — | 31 Mar 2018 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.3%
|
398,311
|
$47,438,000 | — | 31 Mar 2018 | |
| Slate Path Capital LP |
13F
|
Company |
0.29%
|
375,000
|
$44,663,000 | — | 31 Mar 2018 | |
| FARALLON CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.28%
|
370,000
|
$44,067,000 | — | 31 Mar 2018 | |
| TWO SIGMA ADVISERS, LP |
13F
|
Company |
0.27%
|
357,222
|
$42,545,000 | — | 31 Mar 2018 | |
| Legal & General Group Plc |
13F
|
Company |
0.27%
|
348,570
|
$41,515,000 | — | 31 Mar 2018 | |
| CREDIT SUISSE AG/ |
13F
|
Company |
0.24%
|
312,530
|
$37,222,000 | — | 31 Mar 2018 | |
| LORD, ABBETT & CO. LLC |
13F
|
Company |
0.23%
|
297,210
|
$35,398,000 | — | 31 Mar 2018 | |
| Swiss National Bank |
13F
|
Company |
0.22%
|
282,900
|
$33,693,000 | — | 31 Mar 2018 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.21%
|
277,352
|
$33,033,000 | — | 31 Mar 2018 | |
| D. E. Shaw & Co., Inc. |
13F
|
Company |
0.21%
|
271,061
|
$32,283,000 | — | 31 Mar 2018 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
0.19%
|
256,376
|
$30,534,000 | — | 31 Mar 2018 | |
| Sumitomo Mitsui Trust Group, Inc. |
13F
|
Company |
0.19%
|
255,185
|
$30,393,000 | — | 31 Mar 2018 | |
| Casdin Capital, LLC |
13F
|
Company |
0.19%
|
250,000
|
$29,775,000 | — | 31 Mar 2018 | |
| Rockefeller Capital Management L.P. |
13F
|
Company |
0.19%
|
247,754
|
$29,507,000 | — | 31 Mar 2018 | |
| RTW INVESTMENTS, LP |
13F
|
Company |
0.19%
|
246,229
|
$29,326,000 | — | 31 Mar 2018 | |
| ADAGE CAPITAL PARTNERS GP, L.L.C. |
13F
|
Company |
0.18%
|
240,000
|
$28,584,000 | — | 31 Mar 2018 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.18%
|
235,400
|
$28,036,000 | — | 31 Mar 2018 | |
| CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM |
13F
|
Company |
0.17%
|
218,599
|
$26,035,000 | — | 31 Mar 2018 | |
| NEW YORK STATE COMMON RETIREMENT FUND |
13F
|
Company |
0.16%
|
215,481
|
$25,664,000 | — | 31 Mar 2018 | |
| KORNITZER CAPITAL MANAGEMENT INC /KS |
13F
|
Company |
0.16%
|
213,815
|
$25,465,000 | — | 31 Mar 2018 | |
| TOBAM |
13F
|
Company |
0.16%
|
209,449
|
$24,945,000 | — | 31 Mar 2018 |
Institutional Holders of ALNYLAM PHARMACEUTICALS, INC. - Common Stock (ALNY) as of Q2 2018
As of 30 Jun 2018,
ALNYLAM PHARMACEUTICALS, INC. - Common Stock (ALNY) was held by
303 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
91,541,386 shares.
The largest 10 holders included
FMR LLC, WELLINGTON MANAGEMENT GROUP LLP, VANGUARD GROUP INC, BlackRock Inc., PRICE T ROWE ASSOCIATES INC /MD/, DODGE & COX, BAILLIE GIFFORD & CO, STATE STREET CORP, PERCEPTIVE ADVISORS LLC, and UBS ASSET MANAGEMENT AMERICAS INC.
This page lists
303
institutional shareholders reporting positions in this security
for the Q2 2018 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2018 vs Q1 2018 Across Filers
Q1 2018 holders
285
Q2 2018 holders
303
Holder diff
18
| Investor | Q1 2018 Shares | Q2 2018 Shares | Share Diff | Share Chg % | Q1 2018 Value $ | Q2 2018 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.